JP2006514607A - 長時間持続性ナトリウム排泄増加性ペプチド誘導体 - Google Patents

長時間持続性ナトリウム排泄増加性ペプチド誘導体 Download PDF

Info

Publication number
JP2006514607A
JP2006514607A JP2004523679A JP2004523679A JP2006514607A JP 2006514607 A JP2006514607 A JP 2006514607A JP 2004523679 A JP2004523679 A JP 2004523679A JP 2004523679 A JP2004523679 A JP 2004523679A JP 2006514607 A JP2006514607 A JP 2006514607A
Authority
JP
Japan
Prior art keywords
absent
ala
arg
seq
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004523679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514607A5 (enExample
Inventor
ドミニク ピー． ブリドン，
ピーター バキス，
ジュリー カレッテ，
フランス レクレア，
ロジャー レガー，
マーティン ロビタイル，
Original Assignee
コンジュケム，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンジュケム，インコーポレーテッド filed Critical コンジュケム，インコーポレーテッド
Publication of JP2006514607A publication Critical patent/JP2006514607A/ja
Publication of JP2006514607A5 publication Critical patent/JP2006514607A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
JP2004523679A 2002-07-31 2003-07-29 長時間持続性ナトリウム排泄増加性ペプチド誘導体 Pending JP2006514607A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40041302P 2002-07-31 2002-07-31
US40019902P 2002-07-31 2002-07-31
PCT/CA2003/001097 WO2004011498A2 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009273992A Division JP2010047614A (ja) 2002-07-31 2009-12-01 長時間持続性ナトリウム排泄増加性ペプチド誘導体

Publications (2)

Publication Number Publication Date
JP2006514607A true JP2006514607A (ja) 2006-05-11
JP2006514607A5 JP2006514607A5 (enExample) 2006-09-07

Family

ID=31191354

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004523679A Pending JP2006514607A (ja) 2002-07-31 2003-07-29 長時間持続性ナトリウム排泄増加性ペプチド誘導体
JP2009273992A Pending JP2010047614A (ja) 2002-07-31 2009-12-01 長時間持続性ナトリウム排泄増加性ペプチド誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009273992A Pending JP2010047614A (ja) 2002-07-31 2009-12-01 長時間持続性ナトリウム排泄増加性ペプチド誘導体

Country Status (5)

Country Link
EP (1) EP1530588A2 (enExample)
JP (2) JP2006514607A (enExample)
AU (1) AU2003246500A1 (enExample)
CA (1) CA2488348A1 (enExample)
WO (1) WO2004011498A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008162987A (ja) * 2006-12-31 2008-07-17 Toshiko Koide 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法
JP2014506584A (ja) * 2011-02-23 2014-03-17 マデライン ファーマシューティカルズ ピーティーワイ リミテッド うっ血性心不全を処置するための治療方法
JP2021073234A (ja) * 2015-05-29 2021-05-13 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬、外用剤および化粧料

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
WO2002066511A2 (en) 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US8071560B2 (en) 2004-02-17 2011-12-06 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
ATE459370T1 (de) 2002-11-26 2010-03-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
AU2005227870A1 (en) 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
ATE496060T1 (de) 2004-07-15 2011-02-15 Univ Queensland Proteinartige verbindungen und anwendungen davon
MX2007010930A (es) * 2005-03-07 2008-03-14 Mondobiotech Licensing Out Ag Formulacion de aviptadil.
WO2006108686A2 (en) * 2005-04-14 2006-10-19 Aic Bnp agonists
US20080227713A1 (en) * 2005-10-03 2008-09-18 Protter Andrew A Oxidized Human Bnp
KR20080098216A (ko) * 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
US20100310561A1 (en) * 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
JP2010532323A (ja) 2007-07-06 2010-10-07 セラテクノロジーズ インコーポレイテッド アルファ−メラニン細胞刺激ホルモン（アルファ−ｍｓｈ）および心房性ナトリウム利尿タンパク質（ａｎｐ）の二機能性融合タンパク質ならびに高血圧および急性腎臓損傷における使用
WO2012013597A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
DE102010032482A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe zur Beeinflussung der natriuretischen Peptid-Rezeptoren A und B und deren Verwendung
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
CN102286092B (zh) 2011-09-14 2014-01-01 深圳翰宇药业股份有限公司 利拉鲁肽的固相合成方法
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
BR112017011900A2 (pt) 2014-12-05 2018-02-27 Alexion Pharma Inc tratamento de ataques com fosfatase alcalina recombinante
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
EP3833377B1 (en) 2018-08-10 2023-11-22 Alexion Pharmaceuticals, Inc. Bone healing at implants using alkaline phosphatase
MX2022007114A (es) 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
IL319526A (en) 2022-09-30 2025-05-01 Extend Biosciences Inc Long-acting parathyroid hormone
WO2024086680A2 (en) 2022-10-21 2024-04-25 Eli Lilly And Company Long-acting natriuretic peptides and uses thereof
CN116284329B (zh) * 2023-04-28 2023-12-08 成都奥达生物科技有限公司 一种长效利钠肽化合物
CN119529033A (zh) * 2024-12-02 2025-02-28 中山大学 一种用于npr-b靶向的超长效多肽及其在骨骼系统病症中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501294A (ja) * 1985-11-05 1988-05-19 カリフォルニア・バイオテクノロジー・インク 心房性ナトリウム尿排泄亢進ペプチド類似化合物
JPH04500363A (ja) * 1989-05-24 1992-01-23 アボツト・ラボラトリーズ 心房ペプチド誘導体
JP2000191688A (ja) * 1985-11-05 2000-07-11 Scios Inc 心房性ナトリウム尿排泄亢進ペプチド類似化合物
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2000070665A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting anti-angiogenic peptides
WO2001017568A2 (en) * 1999-09-07 2001-03-15 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501294A (ja) * 1985-11-05 1988-05-19 カリフォルニア・バイオテクノロジー・インク 心房性ナトリウム尿排泄亢進ペプチド類似化合物
JP2000191688A (ja) * 1985-11-05 2000-07-11 Scios Inc 心房性ナトリウム尿排泄亢進ペプチド類似化合物
JP2002167396A (ja) * 1985-11-05 2002-06-11 Scios Inc 心房性ナトリウム尿排泄亢進ペプチド類似化合物
JPH04500363A (ja) * 1989-05-24 1992-01-23 アボツト・ラボラトリーズ 心房ペプチド誘導体
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2000070665A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting anti-angiogenic peptides
WO2001017568A2 (en) * 1999-09-07 2001-03-15 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
WO2001017614A2 (en) * 1999-09-07 2001-03-15 Conjuchem, Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008162987A (ja) * 2006-12-31 2008-07-17 Toshiko Koide 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法
JP2014506584A (ja) * 2011-02-23 2014-03-17 マデライン ファーマシューティカルズ ピーティーワイ リミテッド うっ血性心不全を処置するための治療方法
JP2021073234A (ja) * 2015-05-29 2021-05-13 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬、外用剤および化粧料
JP2023096139A (ja) * 2015-05-29 2023-07-06 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料
JP7604020B2 (ja) 2015-05-29 2024-12-23 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料

Also Published As

Publication number Publication date
EP1530588A2 (en) 2005-05-18
WO2004011498A2 (en) 2004-02-05
WO2004011498A3 (en) 2004-06-24
AU2003246500A1 (en) 2004-02-16
JP2010047614A (ja) 2010-03-04
CA2488348A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
JP2006514607A (ja) 長時間持続性ナトリウム排泄増加性ペプチド誘導体
US20080199532A1 (en) Long Lasting Natriuretic Peptide Derivatives
JP4280070B2 (ja) 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
US7268113B2 (en) Long lasting growth hormone releasing factor derivatives
JP4115671B2 (ja) 長期間持続するインシュリン向性ペプチド
US7906482B2 (en) Anti-obesity agents
AU2002233089A1 (en) Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
AU2002233082A1 (en) Long lasting growth hormone releasing factor derivatives
ZA200106676B (en) Long lasting insulinotropic peptides.
HK1123312A (en) Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
AU2005218012A1 (en) Long lasting growth hormone releasing factor derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060719

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090929

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100416